<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT01700400</url>
  </required_header>
  <id_info>
    <org_study_id>CRAB CTC 10-001</org_study_id>
    <nct_id>NCT01700400</nct_id>
  </id_info>
  <brief_title>Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer</brief_title>
  <official_title>Phase I Dose Escalation Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Research and Biostatistics Clinical Trials Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Providence Cancer Center, Earle A. Chiles Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cancer Research and Biostatistics Clinical Trials Consortium</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the investigational study drug everolimus&#xD;
      may be used to increase the effectiveness of chemotherapy treatment for patients with&#xD;
      advanced lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Advanced lung cancer remains an incurable disease although new agents and new treatment&#xD;
      strategies have resulted in improved survival outcomes for patients. Most recently there has&#xD;
      been interest in augmenting tumor response to chemotherapy by the addition of drugs which&#xD;
      inhibit tumor cell growth and proliferation. Everolimus is a new cancer drug which works as&#xD;
      an inhibitor of mammalian target of rapamycin (or mTOR), mTOR is a protein that is part of a&#xD;
      signaling pathway which can cause cancer cells to divide. Everolimus when used alone as a&#xD;
      single agent has produced some response as well as prolonged stable disease in both&#xD;
      chemo-naïve and pre-treated non-small cell lung cancer. The goal of this study is to evaluate&#xD;
      the safety of everolimus with combined other cancer drugs called pemetrexed, carboplatin, and&#xD;
      bevacizumab. Pemetrexed and carboplatin are both chemotherapy drugs and bevacizumab inhibits&#xD;
      the growth of new blood vessels.&#xD;
&#xD;
      Patients will be entered onto dosing cohorts of 3 patients according to the following dose&#xD;
      escalation scheme. The first cohort will begin at dose level 1. At least three patients on&#xD;
      each dose level must have completed cycle one before the study leadership (principal&#xD;
      investigators, study statisticians) will allow patients to be enrolled onto the successive&#xD;
      dose level.&#xD;
&#xD;
      Dose Levels: 1, 2, 3&#xD;
&#xD;
      Pemetrexed (mg/m²): 500, 500, 500&#xD;
&#xD;
      Carboplatin (AUC): 5, 6, 6&#xD;
&#xD;
      Bevacizumab (mg/kg): 15, 15, 15&#xD;
&#xD;
      Everolimus (mg/day): 2.5, 2.5, 5.0&#xD;
&#xD;
      The purpose of this study is to determine the maximum tolerated dose, or MTD, for the&#xD;
      combination of everolimus with pemetrexed, carboplatin, and bevacizumab in patients with&#xD;
      Stage IV non-squamous, non small cell lung cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Define the Maximum Tolerated Dose (MTD) and Recommended Phase Two Dose (RPTD) of the combination of everolimus with pemetrexed, carboplatin, and bevacizumab in patients with Stage IV non-squamous NSCLC.</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Pemetrexed, carboplatin and bevacizumab will be given intravenously on day 1 of a 21-day cycle with doses determined by the dose level to which the patient is assigned.&#xD;
Everolimus will be taken orally days 1-21 of a 21-day cycle. There will be no rest between each 21 day cycle. Tumor scans will be done every 2 treatment cycles. Patients who are not progressing and who are tolerating therapy will be treated with 6 cycles of Pem/Carbo/Bev/Everolimus followed by maintenance Pem/Bev/Everolimus, which will be continued if there is no tumor progression and the patient is tolerating therapy. If there is toxicity related specifically to one of the maintenance drugs, that drug will be discontinued and the other drugs will be maintained.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Dose Limiting Toxicity (DLT) adverse events related to everolimus/pemetrexed/carboplatin/bevacizumab administration in patients with Stage IV non-squamous NSCLC. DLTs will be defined during cycle 1 only. Grading of adverse events will be according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.&#xD;
Hematologic Adverse Events are defined as:&#xD;
Grade 4 neutropenia lasting greater than 5 days; Grade 3 or 4 febrile neutropenia; and/or Grade 4 thrombocytopenia&#xD;
Non-hematologic Adverse Events are defined as:&#xD;
Grade 3 or greater non-hematologic excluding the following:&#xD;
Hypersensitivity reaction grade 3 or 4 occurring on day 1 or day 15; Nausea/vomiting grade 3 or 4 in the absence of optimal antiemetics; Diarrhea grade 3 or 4 in the absence of optimal anti-diarrheal therapy; Asthenia grade 3 or 4 of less than 2 weeks duration; and/or Hyperglycemia grade 3 or 4 temporally related to corticosteroid pre-or post-medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor efficacy associated with administration of everolimus/pemetrexed/carboplatin/bevacizumab administration in patients with Stage IV non-squamous NSCLC.</measure>
    <time_frame>up to 2 years</time_frame>
    <description>number of patients with a response according to the Response Evaluation Criteria in Solid Tumors (RECIST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>time from start of treatment to time of progression or death (overall PFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>measured from the start of treatment to time of death.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental Phase I Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pemetrexed: intravenous; 500 mg/m² for Dose Levels 1, 2 and 3&#xD;
Carboplatin: intravenous; 5 AUC for Dose Level 1; 6 AUC for Dose Levels 2 and 3&#xD;
Bevacizumab: intravenous; 15 mg/kg for Dose Levels 1, 2, and 3&#xD;
Everolimus: oral, 2.5 mg/day for Dose Levels 1 and 2; 5.0 mg/day for Dose Level 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <arm_group_label>Experimental Phase I Dose Escalation</arm_group_label>
    <other_name>Afinitor</other_name>
    <other_name>Zortress</other_name>
    <other_name>RAD001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <arm_group_label>Experimental Phase I Dose Escalation</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>Experimental Phase I Dose Escalation</arm_group_label>
    <other_name>Paraplatin</other_name>
    <other_name>CBDCA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>Experimental Phase I Dose Escalation</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Inclusion Criteria:&#xD;
&#xD;
               1. Signed informed consent&#xD;
&#xD;
               2. Confirmed diagnosis of Stage IV non-squamous non-small cell lung cancer&#xD;
&#xD;
               3. CT of the chest, abdomen, and pelvis which shows metastatic disease. If the&#xD;
                  patient has had previous radiation to the marker lesion(s), there must be&#xD;
                  evidence of progression since the radiation.&#xD;
&#xD;
               4. At least one measurable site of disease according to RECIST criteria that has not&#xD;
                  been previously irradiated. If the patient has had previous radiation to the&#xD;
                  marker lesion(s), there must be evidence of progression since the radiation.&#xD;
&#xD;
               5. Age ≥ 18 years&#xD;
&#xD;
               6. Normal blood function levels as evidenced by laboratory tests.&#xD;
&#xD;
               7. Adequate liver, kidney and blood chemistry function.&#xD;
&#xD;
               8. Adequate blood clotting levels&#xD;
&#xD;
               9. Urine dipstick levels of protein must be between 0-1+.&#xD;
&#xD;
              10. Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 mmol/L AND fasting triglycerides&#xD;
                  ≤ 2.5 x IULN. Testing must be performed within 14 days prior to enrollment.&#xD;
&#xD;
              11. The ability to interrupt NSAIDS 2 days before (5 days for long-acting NSAIDs),&#xD;
                  the day of, and 2 days following administration of pemetrexed.&#xD;
&#xD;
              12. No prior treatment with everolimus. Prior treatment with pemetrexed or&#xD;
                  carboplatin is allowed, provided no disease progression with prior exposure to&#xD;
                  drugs. Prior treatment with bevacizumab allowed.&#xD;
&#xD;
          2. Exclusion Criteria:&#xD;
&#xD;
               1. Evidence of severe or uncontrolled systemic disease or any concurrent condition&#xD;
                  which in the Investigator's opinion makes it undesirable for the patient to&#xD;
                  participate in the trial or which would jeopardize compliance with the protocol&#xD;
&#xD;
               2. Clinically significant cardiac event such as Myocardial infarction&#xD;
&#xD;
               3. Inadequately controlled high blood pressure&#xD;
&#xD;
               4. Active gastrointestinal disease resulting in an inability to take oral or enteral&#xD;
                  medication via a feeding tube or a requirement for IVplacement; prior surgical&#xD;
                  procedures affecting absorption; or active peptic ulcer disease&#xD;
&#xD;
               5. Presence of fluid accumulation which cannot be controlled by drainage&#xD;
&#xD;
               6. Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess&#xD;
                  within 6 months prior to enrollment&#xD;
&#xD;
               7. History of stroke within 6 months prior to enrollment&#xD;
&#xD;
               8. History of significant vascular disease within 6 months prior to enrollment(i.e.,&#xD;
                  aortic aneurysm)&#xD;
&#xD;
               9. No unusual bleeding or inability to clot (assuming not on anti-coagulation);&#xD;
                  patients with a history of DVT and/pr pulmonary embolism are excluded&#xD;
&#xD;
              10. Serious non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
              11. Major surgical procedure, open biopsy, or significant traumatic injury within 28&#xD;
                  days prior to enrollment, or anticipation of need for major surgical procedure&#xD;
                  during the course of the study. Core biopsy or other minor surgical procedure,&#xD;
                  excluding placement of a vascular access device, within 7 days prior to Day 1.&#xD;
&#xD;
              12. Untreated brain metastases Radiation treatment than 28 days prior to&#xD;
                  registration. Side effects due to radiation therapy must have resolved.&#xD;
&#xD;
              13. Coughing up of blood&#xD;
&#xD;
              14. Excessive protein in your urine&#xD;
&#xD;
              15. Abnormal levels of lipids in your blood&#xD;
&#xD;
              16. Previous or current malignancies within the last 3 years, with the exception of&#xD;
                  cervical cancer and adequately treated basal cell or squamous cell carcinoma of&#xD;
                  the skin&#xD;
&#xD;
              17. Prior treatment with any investigational drug within the preceding 4 weeks prior&#xD;
                  to enrollment&#xD;
&#xD;
              18. Patients receiving chronic, systemic treatment with corticosteroids or another&#xD;
                  immunotherapy. Topical or inhaled corticosteroids are allowed.&#xD;
&#xD;
              19. Patients must not receive immunization with attenuated live vaccines within one&#xD;
                  week prior to study enrollment or during study period.&#xD;
&#xD;
              20. Patients who have any severe and/or uncontrolled medical conditions or other&#xD;
                  conditions that could affect their participation.&#xD;
&#xD;
              21. HIV positive&#xD;
&#xD;
              22. Impairment of stomach or intestinal function or stomach or intestinal disease&#xD;
                  that may significantly alter the absorption of everolimus (e.g., ulcerative&#xD;
                  disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small&#xD;
                  bowel resection)&#xD;
&#xD;
              23. Female patients who are pregnant or breast feeding, or adults of reproductive&#xD;
                  potential who are not using effective birth control methods. Women of&#xD;
                  childbearing potential must have a negative urine or serum pregnancy test within&#xD;
                  7 days prior to administration of everolimus.&#xD;
&#xD;
              24. Patients who have received prior treatment with an mTOR inhibitor (sirolimus,&#xD;
                  temsirolimus, everolimus)&#xD;
&#xD;
              25. Patients with a known hypersensitivity to everolimus or other rapamycins&#xD;
                  (sirolimus, temsirolimus) or to its excipients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda L. Garland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Crowley, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Research And Bioststistics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tuscon</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research And Biostatistics Clinical Trials Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://oregon.providence.org/patients/programs/providence-cancer-center/Pages/default.aspx</url>
    <description>Providence Cancer Center of Portland, Oregon</description>
  </link>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>September 21, 2012</study_first_submitted>
  <study_first_submitted_qc>October 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2012</study_first_posted>
  <last_update_submitted>November 21, 2014</last_update_submitted>
  <last_update_submitted_qc>November 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung Cancer</keyword>
  <keyword>Non Small Cell Lung Cancer</keyword>
  <keyword>Advanced Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT01700400
org study id: CRAB CTC 10-001
nct id: NCT01700400
lead sponsor: 
collaborator: 
collaborator: 
collaborator: 
has dmc: No
The purpose of this study is to determine whether the investigational study drug everolimus
      may be used to increase the effectiveness of chemotherapy treatment for patients with
      advanced lung cancer.
Advanced lung cancer remains an incurable disease although new agents and new treatment
      strategies have resulted in improved survival outcomes for patients. Most recently there has
      been interest in augmenting tumor response to chemotherapy by the addition of drugs which
      inhibit tumor cell growth and proliferation. Everolimus is a new cancer drug which works as
      an inhibitor of mammalian target of rapamycin (or mTOR), mTOR is a protein that is part of a
      signaling pathway which can cause cancer cells to divide. Everolimus when used alone as a
      single agent has produced some response as well as prolonged stable disease in both
      chemo-naïve and pre-treated non-small cell lung cancer. The goal of this study is to evaluate
      the safety of everolimus with combined other cancer drugs called pemetrexed, carboplatin, and
      bevacizumab. Pemetrexed and carboplatin are both chemotherapy drugs and bevacizumab inhibits
      the growth of new blood vessels.

      Patients will be entered onto dosing cohorts of 3 patients according to the following dose
      escalation scheme. The first cohort will begin at dose level 1. At least three patients on
      each dose level must have completed cycle one before the study leadership (principal
      investigators, study statisticians) will allow patients to be enrolled onto the successive
      dose level.

      Dose Levels: 1, 2, 3

      Pemetrexed (mg/m²): 500, 500, 500

      Carboplatin (AUC): 5, 6, 6

      Bevacizumab (mg/kg): 15, 15, 15

      Everolimus (mg/day): 2.5, 2.5, 5.0

      The purpose of this study is to determine the maximum tolerated dose, or MTD, for the
      combination of everolimus with pemetrexed, carboplatin, and bevacizumab in patients with
      Stage IV non-squamous, non small cell lung cancer.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Define the Maximum Tolerated Dose (MTD) and Recommended Phase Two Dose (RPTD) of the combination of everolimus with pemetrexed, carboplatin, and bevacizumab in patients with Stage IV non-squamous NSCLC.
time frame: up to 2 years
description: Pemetrexed, carboplatin and bevacizumab will be given intravenously on day 1 of a 21-day cycle with doses determined by the dose level to which the patient is assigned.
Everolimus will be taken orally days 1-21 of a 21-day cycle. There will be no rest between each 21 day cycle. Tumor scans will be done every 2 treatment cycles. Patients who are not progressing and who are tolerating therapy will be treated with 6 cycles of Pem/Carbo/Bev/Everolimus followed by maintenance Pem/Bev/Everolimus, which will be continued if there is no tumor progression and the patient is tolerating therapy. If there is toxicity related specifically to one of the maintenance drugs, that drug will be discontinued and the other drugs will be maintained.
measure: Number of Participants with Adverse Events as a Measure of Safety and Tolerability
time frame: up to 2 years
description: Dose Limiting Toxicity (DLT) adverse events related to everolimus/pemetrexed/carboplatin/bevacizumab administration in patients with Stage IV non-squamous NSCLC. DLTs will be defined during cycle 1 only. Grading of adverse events will be according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.
Hematologic Adverse Events are defined as:
Grade 4 neutropenia lasting greater than 5 days; Grade 3 or 4 febrile neutropenia; and/or Grade 4 thrombocytopenia
Non-hematologic Adverse Events are defined as:
Grade 3 or greater non-hematologic excluding the following:
Hypersensitivity reaction grade 3 or 4 occurring on day 1 or day 15; Nausea/vomiting grade 3 or 4 in the absence of optimal antiemetics; Diarrhea grade 3 or 4 in the absence of optimal anti-diarrheal therapy; Asthenia grade 3 or 4 of less than 2 weeks duration; and/or Hyperglycemia grade 3 or 4 temporally related to corticosteroid pre-or post-medication
measure: Antitumor efficacy associated with administration of everolimus/pemetrexed/carboplatin/bevacizumab administration in patients with Stage IV non-squamous NSCLC.
time frame: up to 2 years
description: number of patients with a response according to the Response Evaluation Criteria in Solid Tumors (RECIST)
measure: Progression-free survival (PFS)
time frame: up to 2 years
description: time from start of treatment to time of progression or death (overall PFS)
measure: Overall Survival (OS)
time frame: up to 2 years
description: measured from the start of treatment to time of death.
arm group label: Experimental Phase I Dose Escalation
arm group type: Experimental
description: Pemetrexed: intravenous; 500 mg/m² for Dose Levels 1, 2 and 3
Carboplatin: intravenous; 5 AUC for Dose Level 1; 6 AUC for Dose Levels 2 and 3
Bevacizumab: intravenous; 15 mg/kg for Dose Levels 1, 2, and 3
Everolimus: oral, 2.5 mg/day for Dose Levels 1 and 2; 5.0 mg/day for Dose Level 3
intervention type: Drug
intervention name: Everolimus
arm group label: Experimental Phase I Dose Escalation
other name: Afinitor
other name: Zortress
other name: RAD001
intervention type: Drug
intervention name: Pemetrexed
arm group label: Experimental Phase I Dose Escalation
other name: Alimta
intervention type: Drug
intervention name: Carboplatin
arm group label: Experimental Phase I Dose Escalation
other name: Paraplatin
other name: CBDCA
intervention type: Drug
intervention name: Bevacizumab
arm group label: Experimental Phase I Dose Escalation
other name: Avastin
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Linda L. Garland, MD
role: Principal Investigator
affiliation: University of Arizona
last name: John Crowley, PhD
role: Study Chair
affiliation: Cancer Research And Bioststistics
facility: 
facility: 
facility: 
facility: 
country: United States
url: http://oregon.providence.org/patients/programs/providence-cancer-center/Pages/default.aspx
description: Providence Cancer Center of Portland, Oregon
responsible party type: Sponsor
mesh term: Lung Neoplasms
mesh term: Carcinoma, Non-Small-Cell Lung
mesh term: Bevacizumab
mesh term: Carboplatin
mesh term: Pemetrexed
mesh term: Everolimus